FR3072875B1 - COMPOSITION CONSISTING OF A GLP-2 RECEPTOR AGONIST AND A CO-POLYAMINOACID CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS - Google Patents

COMPOSITION CONSISTING OF A GLP-2 RECEPTOR AGONIST AND A CO-POLYAMINOACID CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS Download PDF

Info

Publication number
FR3072875B1
FR3072875B1 FR1760307A FR1760307A FR3072875B1 FR 3072875 B1 FR3072875 B1 FR 3072875B1 FR 1760307 A FR1760307 A FR 1760307A FR 1760307 A FR1760307 A FR 1760307A FR 3072875 B1 FR3072875 B1 FR 3072875B1
Authority
FR
France
Prior art keywords
glp
receptor agonist
polyaminoacid
composition consisting
carboxylate charges
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1760307A
Other languages
French (fr)
Other versions
FR3072875A1 (en
Inventor
Remi Soula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to FR1760307A priority Critical patent/FR3072875B1/en
Priority to PCT/EP2018/079912 priority patent/WO2019086559A1/en
Publication of FR3072875A1 publication Critical patent/FR3072875A1/en
Application granted granted Critical
Publication of FR3072875B1 publication Critical patent/FR3072875B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

[0001] L'invention concerne une composition stable physiquement sous forme d'une solution aqueuse injectable, dont le pH est compris entre 6,0 et 8,0, comprenant au moins : a) un agoniste du récepteur du GLP-2 ou un analogue du GLP-2, ou h[Gly2]GLP-2, et b) un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes Hy, ledit co-polyaminoacide étant constitué d'unités glutamiques ou aspartiques et lesdits radicaux hydrophobes Hy.The invention relates to a physically stable composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, comprising at least: a) a GLP-2 receptor agonist or a analogue of GLP-2, or h [Gly2] GLP-2, and b) a co-polyamino acid carrying carboxylate charges and hydrophobic Hy radicals, said co-polyamino acid consisting of glutamic or aspartic units and said hydrophobic Hy radicals.

FR1760307A 2017-10-31 2017-10-31 COMPOSITION CONSISTING OF A GLP-2 RECEPTOR AGONIST AND A CO-POLYAMINOACID CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS Expired - Fee Related FR3072875B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1760307A FR3072875B1 (en) 2017-10-31 2017-10-31 COMPOSITION CONSISTING OF A GLP-2 RECEPTOR AGONIST AND A CO-POLYAMINOACID CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS
PCT/EP2018/079912 WO2019086559A1 (en) 2017-10-31 2018-10-31 Composition comprising a glp-2 receptor agonist and a co-polyamino acid carrying carboxylate charges and hydrophobic radicals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1760307 2017-10-31
FR1760307A FR3072875B1 (en) 2017-10-31 2017-10-31 COMPOSITION CONSISTING OF A GLP-2 RECEPTOR AGONIST AND A CO-POLYAMINOACID CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS

Publications (2)

Publication Number Publication Date
FR3072875A1 FR3072875A1 (en) 2019-05-03
FR3072875B1 true FR3072875B1 (en) 2020-11-06

Family

ID=61521593

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1760307A Expired - Fee Related FR3072875B1 (en) 2017-10-31 2017-10-31 COMPOSITION CONSISTING OF A GLP-2 RECEPTOR AGONIST AND A CO-POLYAMINOACID CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS

Country Status (1)

Country Link
FR (1) FR3072875B1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9905416D0 (en) * 1999-03-09 1999-05-05 Allelix Biopharma Small molecules having GLP-2 like activity
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
CN107583039A (en) * 2012-01-09 2018-01-16 阿道恰公司 PH is 7 and the Injectable solution at least containing the PI basal insulins for being 5.8 to 8.5 and substitution copolymerization (amino acid)
WO2014096440A2 (en) * 2012-12-21 2014-06-26 Novozymes Biopharma Dk A/S Composition
FR3052071B1 (en) * 2016-06-07 2018-09-07 Adocia COMPOSITIONS IN THE FORM OF AQUEOUS INJECTABLE SOLUTION COMPRISING GLUCAGON AND A CO-POLYAMINOACID

Also Published As

Publication number Publication date
FR3072875A1 (en) 2019-05-03

Similar Documents

Publication Publication Date Title
MX2018015070A (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid.
FR3001896B1 (en) PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISO-ELECTRIC POINT IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIC ANIONIC POLYMER
SA518400588B1 (en) Injectable Solution at PH 7 Comprising at Least One Basal Insulin The PI of Which is From 5.8 to 8.5 and A Co-Polyamino Acid Bearing Carboxylate Charges and Hydrophobic Radicals
GT200600038A (en) SMALL AGONISTS AND THEIR USES
GEP20207139B (en) Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
WO2019110797A8 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
EA201790997A1 (en) COMPOSITIONS OF GLYKOPEPTIDES
FR3001895B1 (en) PH7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISOELECTRIC POINT IS INCLUDED IN 5.8 AND 8.5 AND AN ANIONIC COMPOUND CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
FR3057457B1 (en) HEALING PILLAR FOR DENTAL RESTORATION
MX2020005916A (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid.
MA51600A (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND A CO-POLYAMINOACID
MX2020005915A (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid.
FR3020952B1 (en) FAST-ACTING INSULIN FORMULATION COMPRISING SUBSTITUTED ANIONIC COMPOUND AND POLYANIONIC COMPOUND
AR092691A1 (en) PHARMACEUTICAL COMPOSITION THAT REBAMIPIDA INCLUDES
FR3072875B1 (en) COMPOSITION CONSISTING OF A GLP-2 RECEPTOR AGONIST AND A CO-POLYAMINOACID CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS
FR3079414B1 (en) COMPOSITION COMPRISING A GLP-2 RECEPTOR AGONIST AND A CO-POLYAMINOACID CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
NO20082928L (en) Process for sol-gel processing
FR3061023B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
FR3013607B1 (en) INK COMPOSITION BASED ON NANOPARTICLES
FR3074682B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
FR3074680B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
FR3083085B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND A CO-POLYAMINOACID
FR3074683B1 (en) COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
EP3888778A3 (en) Fine bubble generation apparatus
FR3074681B1 (en) PH 7 INJECTION SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARRYING CARBOXYLATES AND HYDROPHOBIC RADICALS

Legal Events

Date Code Title Description
PLSC Publication of the preliminary search report

Effective date: 20190503

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

ST Notification of lapse

Effective date: 20220605